NOVOCURE LIMITED

(NVCR)
  Report
Real-time Estimate Cboe BZX  -  12:06 2022-06-28 pm EDT
73.36 USD   -1.78%
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Index
CI
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Growth Index
CI
06/21NovoCure Enrolls First Patient in Study of Tumor Treating Fields, Keytruda Combination to Treat Lung Cancer
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 8 34017 6157 7957 812--
Enterprise Value (EV)1 8 31217 8108 1488 1058 0517 931
P/E ratio -1 204x865x-134x-129x-131x-184x
Yield ------
Capitalization / Revenue 23,7x35,6x14,6x14,2x13,2x11,5x
EV / Revenue 23,7x36,0x15,2x14,7x13,6x11,6x
EV / EBITDA 1 102x450x-239x-182x-162x-510x
Price to Book 38,5x37,2x19,0x17,0x14,5x11,6x
Nbr of stocks (in thousands) 98 969101 797103 819104 586--
Reference price (USD) 84,317375,174,774,774,7
Announcement Date 02/27/202002/25/202102/24/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 351494535552592681
EBITDA1 7,5539,6-34,1-44,4-49,6-15,6
Operating profit (EBIT)1 -0,9130,4-44,3-47,9-32,5-24,2
Operating Margin -0,26%6,15%-8,29%-8,68%-5,49%-3,55%
Pre-Tax Profit (EBT)1 -8,8218,1-52,1-58,3-62,4-37,4
Net income1 -7,2319,8-58,4-62,6-62,0-43,3
Net margin -2,06%4,01%-10,9%-11,4%-10,5%-6,36%
EPS2 -0,070,20-0,56-0,58-0,57-0,41
Dividend per Share ------
Announcement Date 02/27/202002/25/202102/24/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 134133138135138141
EBITDA1 -5,82-20,71,80-11,6-14,6-16,9
Operating profit (EBIT)1 -8,55-23,4-0,81-13,4-14,7-19,0
Operating Margin -6,40%-17,6%-0,59%-9,90%-10,7%-13,5%
Pre-Tax Profit (EBT)1 -10,5-25,6-2,52-15,0-17,3-23,4
Net income1 -13,1-26,5-4,65-15,4-16,9-21,5
Net margin -9,82%-19,9%-3,38%-11,4%-12,3%-15,3%
EPS2 -0,13-0,25-0,04-0,14-0,16-0,20
Dividend per Share ------
Announcement Date 10/28/202102/24/202204/28/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 -195353293240119
Net Cash position1 27,9-----
Leverage (Debt / EBITDA) -3,70x4,94x-10,4x-6,60x-4,83x-7,67x
Free Cash Flow1 16,184,258,636,863,798,9
ROE (Net Profit / Equities) -4,38%5,71%-13,2%-16,5%-13,6%-0,66%
Shareholders' equity1 1653474443804546 576
ROA (Net Profit / Asset) -1,77%2,59%-5,33%-6,12%-5,45%-0,29%
Assets1 4107661 0961 0221 13714 931
Book Value Per Share2 2,194,663,954,405,156,46
Cash Flow per Share ------
Capex1 10,515,024,225,424,026,3
Capex / Sales 2,98%3,03%4,52%4,60%4,05%3,86%
Announcement Date 02/27/202002/25/202102/24/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 7 811 535 360
Net sales (USD) 535 031 000
Number of employees 1 167
Sales / Employee (USD) 458 467
Free-Float 86,5%
Free-Float capitalization (USD) 6 758 517 424
Avg. Exchange 20 sessions (USD) 70 811 221
Average Daily Capital Traded 0,91%
EPS & Dividend